---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-134588"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:55:35.248186+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Soleno completes enrollment in DCCR PWS study; triggers $10M capital infusion

## Summary
- Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
- Top-line data expected Q3 2023; FDA previously acknowledged data could support an NDA submission.
- Completion triggers $10 million capital infusion from Nantahala, Abingworth, and Vivo per Dec 2022 SPA.
- 77 patients enrolled at 17 US and 5 UK sites; 93% of total 83 patients participated.

## SEC filing metadata
- accession: 0001193125-23-134588
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312523134588/0001193125-23-134588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312523134588/d363623d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-134588
- JSON: https://secwatch.observer/filing/0001193125-23-134588.json
- Plain text: https://secwatch.observer/filing/0001193125-23-134588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.